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Based on "mlim) acid sequence and computer modeling, two conflicting three-dimensional mndcls of die dopamine l)~ 
receptor have beth proposed. One m~del (Dahl et al., 1991, Prec. Natl. Acad. Sci. USA 88, 8111) stlggcsts that dopamine 
interacts with asp'~"latc 80 of transmcmbranc (TM) 2 and asparaginc 390 of TM6 with the transmenlbranes arranged in a 
clockwise manner, white a second m,,del (Hiberl et al., 1991, Mol. Pharmacol. 40, 8) suggests that dopaminc interacts with 
aspartatc 114 of TM3 and the serines of TM5 (194 and 197) with the transmcmbranes arranged m a countcrclockwise manner 
when viewed from the cxtracellular space. The present study tests the latter model by selectively mutating aspartate 114 and 
serines 194 and !c-~7 ,af the t;uman &~pamine D, receptor by site-directed rnutagcnesis. In addition, two methioeincs (116 and 
117) were mutated to evaluate whether residues near aspartate (1i4) of the dopaminc D 2 receptor are critical in differentiating 
dopamine receptor agonists from adrenoceptor agonists. Removal of the negative charge with the mutation of aspartatc (114) to 
either asparagine or glycinc led to a to!al loss ¢~f both agonist and antagonist binding, lndNidual or dual methinnine mutations in 
positions 116 and 117, to make the dopamine D 2 binding pocket more closely resemble the/,12-adrenoceptor, did not result ill a 
change in selectivity toward noradrenergic ag~mists or anla[,,onists. Tile scrine mutations revealed interesting differences between 
the dopamine D 2 receptor and the adrenoceptors. In particular serine 197 appeared more imp,~rtant than serine 194 for agonist 
binding. In addition, the binding of Olle agonist (NdH.37) was un,J'fcctcd by individual scrinc nlutathms, white the binding of 
some antagonists, such as raclopride and spip,.'rone, was significantly al,.cred. These fi,ldings are discussed in relation to ligand 
slrucltlrc and their interactions with the putative binding pocket. 
1)opamine 1)~ receptors: Mut~,gcnesis: Receptor binding: Catecholaminc receptors 
1. lntro,;uctiol~,, 
The iecent  cloning (Bunzow et al., 1988; Dearry ct 
al., It)90; Mahan et al., 199{); Monsma et al., 1990; 
Soko]off el al., 1990; Sunahara et al., 19'~fl. 1991; Zhou 
el a!., !99(t; Van Tot c t a l . ,  19nl) of the dopamin¢ 
receptors ( D ~ - D  5) suggests that they are members  of a 
larger family of G-protein coupled, seven t ransmem- 
brane receptors (Gilman, 1987) whose other  members  
include the adrenneeptor  (Dixon et al., 1986; Friellc ct 
al., 1987; Kobilka c ta l . ,  1987a,b; C' l tecchia et al., 1988; 
Rcg;m et a[., 1988), muscarinic acetylcholine receptor  
(Bonner  et al., 1987; Peralta et al., 1987: Ramacimn- 
dran ct al., 1989), and peptidergic reccoiors  (Masu el 
al., 1987; Hershey and Krause, 19911; Tanaka ct al., 
199{)). These receplors share a common structural too- 
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tif and arc similar to the better  characterized rhodopsir, 
protein (Henderson el ill., 1990)which spans the ph, snla 
membra~'e :;c,,en tim'?:;; widi the t ransmcmbrane (TM) 
domains forming a binding pocket. The N-termina! 
region is thought lo be extracellular and the C O O H -  
terminus intracellular. Three  intracelh:l.ir and threc 
cxtracellular loops are lormcd whh tiffs organization 
and the second and third cytoplasmic loops are lhougtlt 
to be involved iv. G-protein cnupling (Kobilka et al., 
1988; Str.'.:der et al., 198"7.:). 
Site-directed mutagencsis studies of tiw / le-ad,eno- 
ceplor  suggest that specific amino acids deep in the 
binding pocket formed by the TM domains arc critical 
for the recognition of catecholamines (Fraser, 1980: 
Strader  et al., 1987, 1989a,b; Neve et al., 1991) In 
particular, aspartatc 79 in Tr',]2 and asparlat_c 113 in 
TM3 arc tht;'.~ght to in{era i wilh the amino group of 
epinephrine and norcpinc: ,hrine (Strader et al., l')[(7b). 
wk'ile two serincs (2/14 and 2U7) in T M 5  form hydrogen 
bonds with the hydroxyl groups of the caicd,ol  rnoiely 
(Strader et a l ,  1989a). S~.v.dics by Strader el al. (1989a) 
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t, ; t the serines in TM5 are important further sugge:,! 
only for ,~goni z ~,nding and their mutation to alaninc 
does not alter afJtagonist binding. 
Site-directed mutagenesis of corresponding residues 
in the a2-adref~ceptor (Wang et al., 1991) suggests 
that there may be differences in the way cate- 
cholamines bi~:3 in ti~e a~- and /32-receptors. Unlike 
the !32-receptor, serine mutations in TM5 of the t~2-re- 
ceptor can still exhibit a :'naximal cAMP inhibition with 
higher agonist concentrations despite a reduced recep- 
tor affinity. In the case of the /32-receptor, simgar 
mutations result in a complete loss of cAMP effects. 
Further, the two series (204 and 207) in TM5 of the 
/32-receptor appear equally necessary for agonist affin- 
ity, while in the az-receptor the serines (200 and 204) 
are asymmetrically important, with serine 204 being 
primary in forming hydrogen bonds with the parahy- 
droxyl group of the catecholamines. In both the a 2- 
and /32-receptors, aspartate 113 of TM3 appears criti- 
cal for agonist and antagonist binding. 
Amino acid analysis of the adrenoceptor (a  l, a 2 , /3 ,  
/32) and the dopamine receptors (D~-D 5) demonstrate 
that the aspartates in TM2 and TM3 and the serines in 
TM5 are conserved across ~:hese cateeholamine recep- 
tors. consistent with a common catecholamine binding 
pocket (table 1). Yet despite this common structure, 
other amino acids likely extend into the binding pocket 
to confer receptor affinity and selectivity. Identifying 
these residues is particularly important for better un- 
derstanding of the catecholamine binding pocket and 
developing more efficacious and selective therapeutic 
drugs. In addition, as the majority of the information 
concerning catecholamine receptor structure has been 
derived from the a 2- and /32-adrenoceptor, it is impor- 
tant to extend these studies to other receptors to 
determine whether subst~:ntial differences may exist. In 
the case of the dopamine receptors, only one site-di- 
rected mutagenesis study is available in which the 
effects of aspartate 80 mutations on D 2 receptor bind- 
ing were evaluated (Ncve et al., 1991). No intormation 
concerning the aspartate in TM3 or the serines in TM5 
of the dopamine receptors is available. 
Based on the amino acid sequence of the dopamine 
D z receptor and computer modeling, two conflicting 
three-dimensional models of the D 2 receptor have 
been proposed. One model (Dahl et al., 1991) suggests 
that dopamine interacts with aspartate 80 of TM2 and 
asparagine 390 of TM6 with the transmembranes being 
arranged in clockwise manner when viewed from the 
extracellular space. A second model (Hibert et al., 
19911 suggests that dopamine may interact with aspar- 
rate 114 of TM3 and the serines of TM5 (194 and 1971 
with the transmembranes arranged in a counterclock- 
wise manner. To further evaluate these models and 
their relevance to other catecholamine receptors, the 
present study examines the importance of the asparate 
114 by site-directed mutagenesis, altering it to either 
asparagine or glycine, two neutral amino acids. The 
roles of serines 194 and 197 in TM5 of the D 2 receptor 
in agonist and antagonist binding were also examined 
to determine whether dopaminergic comoounds inter- 
act with these amino acid residues. Pharmacological 
data with dopaminergic ligands (Seeman, 1981) indi- 
cate "' . . . .  ~'~ • ttldt tti  meta-hydroxyl group ot dopaminergic 
agonists is primarily important in stabilizing agonist 
binding, suggesting that the scrine residues (194 and 
197) of the D 2 receptor may not be equally important 
for binding affinity as appears to be the case for the 
/32-receptor. D 2 receptors with single o~ dual serine 
(194 and 197) mutations were, therefore, evaluated in 
the present study. 
As the chemical structures of dopamine and nor- 
epinephrine are nearly identical, differing only in a 
beta-hydroxyl group present in norepinephrine, we hy- 
pothesized that there may be specific amino acids near 
the critical aspartate (114) in TM3 that might aid in 
conferring receptor selectivity To test this possibility, 
two adjacent methionines in TM3 of the D 2 receptor 
in positions 116 and 117 (table 1) were mutated indi- 
vidually or in combination to leucine (116) and cysteine 
(1171 to more closely approximate the amino _acid ~e- 
quence of the/32-adrenoceptor. Methionine 116 is con- 
served across all the dopamine receptors ( D r D s ) ,  but 
is replaced by leucine in the adrenoceptors (a~, a 2, H~, 
/32). Methionine in position 117 is conserved in D 2 and 
D 3, but is replaced by either cysteine (D I and D 5) or 
leucine (D 4) in other dopamine receptors. It was hy- 
pothesized that one or both these methionines may 
provide steric interference with the side chain OH 
group of epinephrine and norepinephrine, but would 
allow dopamine, without this moiety, to bind to the D,  
receptor. 
2. Materials and methods 
Z 1. Mutagenesis and expression 
Mutant receptors of the human D, were prepared 
with the oligonucleotide-directed mutagenesis system 
provided by Amersham. Oligonucleotides (2/t-45 bases) 
were synthesized, purified on polyacrylamide gels 
(20%), and annealed to a MI3 single-stranded bacte- 
riophage that contained the entire protein coding re- 
gion of the human D 2 receptor (1-1627 bp) including 
the 87 bp addition in the tilird cyto,,;olic loop (D2/3). 
Briefly, the method involves extending the oligonu- 
cleotide with Klenow polymerase in the presence of T 4 
DNA ligase to generate a mutant heteroduplex. The 
non-mutated strand is then selectively removed with 
exonuclea'~e digestion and filtration, leaving the mutant 
2(~7 
T A B L E  1 
Amino acid alignments of t ransmembrane three and five o1" the adrenoceptors and dopamine receptors. 
Arrows indicate the aspartate, methionine and serine residues that have been mutated for the D ,  receptor. Bnti~ human (H) and rat (R) 
sequences are l-rovided. 
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A1 (H) . .CDIWAAVDVLCCTASXLSLC.AISLDRY ........... EPF~ALFSSLGSFYIPLAVZLVI4YCR 
A2A (H) . .CEZYLALDVLFCTSSI'VHLCAXSLDRY ........... 0KWYVISSCXGSTFAPCLIMXLY'/VR 
A2B (H) . .CGVYLALDVLFCTSSI~/HLCAXSLDRY ........... ETWYILSSCXGSFFAPCL~/4GLVIq%R 
B1 (H) . .CEZNTSVDVLGVTASIETLCVIALDRY ........... NRAYAIASSWSFYVPLVIMAFVYLR 
B2 (H) . .CEFW~SIDVLCVTASXETLCVZ~VDRY ........... NQAYAIASSI~'SFYV~LVZMVFVYS~ 
B2 (R) . .CEFWTSZDVLCVTASVETLCVIAVDRY ........... NQAYAIASSXVSFYVPL~SR 
D1 (H) . . CNIWVAFD~','~CSTAS'rL.-'qLCVISVDRY . . . . . . . . . . .  SRTY&XSSSVISF'YXPVAIMIVT'ZTR 
D i  (R) . .CNZ',dVAFDZMCSTAS'rLNLCVXSVDRY . . . . . . . . . . .  SR'I"ZAXSSSL'rSFYXPVA.T.MIV'I~ 
0 2  (H) . .CDZFVTLDVMMCTASTLNLCAISIDRY . . . . . . . . . . .  NPAFVVYSSIVSFT',,'PFZVTLLVYIX 
0 2  (R) . . C D X F V T L D ~ T A S Z ~ S I D R Y  . . . . . . . . . . .  NPAFVVYSSI'VSFYVPFIVTLLVYZK 
D3 (R} . ,CDVF~TLDV~V/CTASILNLCAISZDRY ........... NPDFVTYSSVVSFY'~PFGVTVLVYAR 
D4 (H) . .CD~VMLCTASXFNLCAISVDRF ........... DRDYVVYSSVCSFFLPCPL~rr.T~T.YWA 
D5 (H) . .CDVWVAFDI/4CSTASILNLCVISVDRY ........... NRTYAXSSSLXSFYIPVAIMIVTYTR 
strand to regenerate the replicative DNA form that is 
then subcloned in a pCMV expression vector for trans- 
fection into eukaryotic cells. A total of seveJ-~ single 
amino acid mutations were made: Asp (114) to Asn or 
Gly, Met (116) to Leu, Met (117) to Cys or Gly, Set 
(194) to Ala, Ser (197) to Ala. Two dual mutations 
were also designed: Met (116) and Met (117) to Leu 
(116) and Cys (117) and Ser (194) and Ser (197) to Ala 
(194) and Aia (197). All pCMV mutant constructs were 
sequenced to verify that the mutations were correct. 
2.2. Transfection 
COS-1 cells were grown in Dulbeco's modified Ea- 
gle's medium with 10% fetal calf serum and subeul- 
tured into 90 mm tissue culture plates (1-1.5 x I06 
cells) 24 h prior to transient transfection using a cal- 
cium phosphate precipitation procedure (Chert and 
Okayama, 1987). Each 90 mm plate of cells was trans- 
fected with 20/xg of pCMV-D 2 wild type or pCMV-D= 
mutant DNAs. Plasmid DNAs were added to 0.5 ml 
0.25 M CaCI 2 to which 0.5 ml of 2 x BBS (50 mM 
N,N-bis(2-hydroxy-ethyl)-2-aminoethanesulfonic acid. 
280 mM NaCI, 1.5 mM NaHPO a, pH = 6.95) was added. 
This mixture was allowed to remain at 22°C for 10-20 
rain, then slowly dripped onto one 90 mm plate of cells. 
The cells were then grown overnight at 37°C and 3% 
CO2, washed twice in Versine and once in medium and 
allowed to grow for an additional 24 h (37°C, 5% CO 2) 
prior to harvesting. To assess the efficiency of transfec- 
tion across experiments, all studies involved the co- 
transfection of/3-galactosidase that was subcloned into 
pCMV (10 /zg of plasmid)o Based on /3-galactosidase 
assays, transfcction efficiencies using this procedure in 
COS cells ranged from 10 to 40%. 
2.3. Radioligand bblding assays 
At time of cell harvest, the culture medium was 
removed and each plate of cells was then washed with 
10 ml of ligand incubation buffer. For [3H]raclopride 
(New England Nuclear, 62.7-83.4 Ci/mmol)  this buffer 
consisted of 50 mM Tris (pH = 7.4. 25°C), 120 mM 
NaC1, 5 mM KCI, 1 mM MgCI 2 and 0.1% ascorbic 
acid. This buffer was then replaced by fresh ligand 
incubation buffer (7 ml) in which the transfected cells 
were harvested by scraping. For cells harvested for 
[3H]N-0437 (Amersham, 54.(i-98.0 Ci/mmol)  binding 
studies, the same incubation buffer less the 120 mM 
NaCI and 0.1% ascorbic acid was used. Prior to ho- 
mogenization (kinematic polytron), an aliquot ~f the 
celt suspension was saved for ceh counting. The re- 
maining sample was homogenized, with 200 /~1 of the 
homogenate added to each incubation tube bringing 
the total membranc homogenate and ligand volume to 
250/.tl per tube. Nonspccific binding for [SH]raclopride 
and [3H]N-0437 was defined by 1 gM (+)-butaclamol. 
After a 90 min incubation (22°C), membranes were 
filtered lander vacuum through glass filters (Schleicher 
and Scbuelt, No. 32) using a Brandel cell harvester. 
The filters were then rinsed twice with 3.5 ml of 
washing buffer (50 mM Tris (pH = 7.5), 120 mM NaCI, 
5 mM KCI, I mM MgCI z, 4°C) and counted by liquid 
scintillation spectrometry. The wash buffer for ['~H]N- 
0437 was the same as above except that it did not 
contain 120 mM NaCI and 0.1% ascorbic acid. For 
saturation studies a minimum of eight concentrations 
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of  radioligand (10-11.1175 nM) with duplicates were 
used to determine Scatchard pk)ts and all studies were 
replicated at least once. Similarly, competi t ion studies 
used a minimum of eight concentrat ions of unhtbelled 
compounds, performed in duplicate and repeated at 
least once. The  following drugs were used to evaluate  
the affinity of  dopamieergic  agonists and antagonists: 
apomorphine,  bromocriptine,  (+) -bu tac lamol ,  chlor- 
promazine, clozapinc, dopaminc,  LY171555, NPA (N- 
propylnorapomo:phine) ,  and spiperone. Apomorphine ,  
bromocriptine,  and dop:~mine were purchased from 
Sigma (St. Louis, MO, USA), and NPA was purchased 
from Research Biochemical (Natick, MA, USA).  All 
other  compounds were a kind gift from James Woods, 
University of  Michigan. A!I binding data was analyzed 
with the L1GAND program developed by Munson and 
Rodbard ( 19801. 
To assess whether" the mutations al tered the selectiv- 
ity of the dopamine rcceptor,  [~2slJCYP (cyanopindo- 
Iol, New England Nuclear, 21)t)(! C i / m m o l )  binding was 
performed on transfccted ceils. [~2s I!CYP binding stud- 
ies were performed as above cxcept that the incubation 
and wash buffers consisted of 50 mM Tris (pH = 7.4-  
7;6), 12.5 mM MgCI 2, and !.5 mM EDTA.  In addition, 
competit ion studies were performed with epinephrine 
(Sigma, St. Louis, MO, LISA) and [3H]N-0437. 
2.4. ~-Galatosidase (~-gal) assays 
Aliquots (500 /xl) of  the transfected cell ho- 
mogenates  described above were centrifuged at 15,600 
x g  for 1 rain and stored on ice. 200/z l  of the super- 
natant was then added to an equai volume of /3-gal 
assay solution (1.34 m g / m l  O-ni t rophenyl- ,8-D-  
galactoside, 166 mM 2-mercapteothanol ,  51)0 mM 
N a 2 H P O  ~, 1 M KCI, 500 mM MgCI 2) arm transferred 
to a cuvette. The reaction was stopped by ad0~ng 500 
/.tl of 1 M Na2CO.~. Spectrophotometr ic  absorbancc of  
this yellow reaction product was measurcd at 4 t0  nm. 
Absorbance values of the homogenized sample.q were 
compared to a standard curve consiructed with com- 
mercially available /3-galactosidase (Sigma, St. Louis, 
MO, USA) and units of activity were determined.  To 
calculate the percentage of  cells cxr:ressmg /3-gal, 90 
mm cell culture plates were rinsed twice in PBS, fixed 
in a formaldehyde (2 .2%)/g lu ta ra ldehyde  (I).2c;~) solu- 
1 2 3 4 5 6 7 8 9  
28S-- 
18S-- 
Fig. 1. Northern analysis comparing COS-| cells transfccted with the 
D, receptor mutants. The lanes are as follows" (1) Aspll4-Asn, (2) 
Aspll4-Gly, (3) Metll6-Leu, (4) Metll7-C~.';. (5) Melll7-Gly, (6) 
Serl04-Ala, (7) Ser197-Ala, (8) Scr194 and Ser197-Ab!. (9) Met116- 
Leu and Met117-Cys. 
tion for 5 min at 22°C and treated with /3-gal (1 
m g / m l )  tbr 1-12 h at 37°C. Cells positive for /3-galac-  
tosidase yielded a blue color. 
2.5. Northern analysis 
To aid in determining whether  the receptor  mutants  
were expressed, m R N A  was extracted from cells trans- 
fected with thc D ,  wild type and mutant  D 2 receptors 
and Northern analysis was performed.  R N A  samples 
from transfected COS-1 cells were extracted with 4 M 
guanidium isothiocyanate and resuspend~d in 5()% for- 
mamide,  20 mM morphol inepropanesul fonic  acid 
(MOPS,  pH 7.0), 5 mM sodium acetate,  1 mM EDTA,  
and 2.2 M formaldehyde.  The  R N A  was dcnaturcd at 
65°C for ll) rain and c lec t rophoresed on a 1% agarose 
gel containing 2.2 M formaldehyde,  2(1 mM MOPS (pH 
7.It), 5 mM sodium acetate,  and 1 mM EDTA.  The 
R N A  samples wcre passively transfcrrcd to Nytran 
mcmbrancs  (Schlcicher and Schuell) with 10 x SSC 
(300 mM NaCI, 30 mM sodium citrate,  pH 7.2) and 
baked for 2 h at 8¢)°C. Thc  membranes  were then 
prchybridizcd in 50% formamide,  5 x SSC, 5 x 
Dcnhardt ' s ,  50 mM sodium phosphate  (pH 6.5), and 
11.5% SDS for a mininmm of 2 h at 42°C. The  hy- 
bridization buffcr was thc same as thc prehybridization 
buffer except that it contained 1 x Denhardt ' s ,  20 mM 
sodium phosphate,  and 10% dextran sulfate. A ran- 
dom-pr imcd 32p-labelled fragmcnt ( B s t E i l / K p n l ) o f  
thc human D 2 receptor  was used in the hybridization 
TABLE 2 
Kj values (nM + S.D.) of [~H]raclopride. 
Asp114-Asn Asp114-G!y Mei116-Lcu Met117-Cys Mett 17-Gly Set 194-Ata Ser197-Ala Wild type 
NSB NSB (). 1811 11.124 0.211 0.235 11.714 ,L 0.166 
) + 0.07~ ( + 0.01)5) ( + 0.024) ( ± 0.020) ( + 0.044) ( _+ 0.015) 
Aspartate mutations in position 114 failed to show specific binding (NSB). Analysis of variance of the remaining mutants indicated that there was 
a difference between mutants anti wild type D 2 ( F  = 106515. P < 0.0001). Post-hoe Scheffe comparisons suggested that the serine It17 mutation 
significantly reduced C' P < 0.05) the affinity for raclopride. 
TABLE 3 
K d Values (riM ± S.D.) of [ 3tt 1N-0437. 
209 
Asp114-Ash Asp114-Gly Met116-Leu Moll 17-Cys Metl 17-Gly Ser194-Ata Ser197-Ala Ser194-Ala Wild type 
Sert97-Ala 
NSB NSB 0.771 (I.906 1.14 ~).926 0.906 NSB 1),880 
( ± 0.244) ( ± 0Jig0) ( ± 11.39) ( ± (1.2641 ( +_ 0.118) ( ± 0.096) 
Aspartate 114 mutations and dual serinc 194 and 197 mutations demonstrated no specific binding (NSB). Other mulations failed to produce any 
differences in binding compared to the wild type D z, 
buffer  to probe the filter overnight  at 42°C. The blot 
was washcd once in 2 x SSC and 0.5% SDS at 22°C for 
~'5 min, t ransferred to 0.1 x SSC and 0.5% SDS at 
65°C for 30 min and apposed to X-ray film at 22°C for 
t0 rain. 
In all of the above procedures,  thc D~ mutants and 
the wild type human D~ receptor  were assessed in 
parallel. The  data  wcrc analyzed by ei ther one- or 
two-way A N O V A s  and Schiffc post-hoe comparisons 
were performed.  
3. Results  
3.1. Ligand binding 
The affinity of  [3H]raclopride for the wild type D 2 
varied (0.17-0.55 nM) with trit iated ligand shipments 
at~,d in all the following experhnents  the wild type D~ 
was evaluated with the D ,  mutants using the same 
shipment of trit iatcd ligand. The agonist [3H]N-0437 
also failed to consistently demonst ra te  two binding 
sites with transiently transfected COS cells. In most 
cases, the L I G A N D  program fit the data best to one 
site and these are the affinities prescnted in table 3. 
3.2. Transfection controls 
All mutant  receptors,  when transiently transfected 
into COS cells, expressed high levels of  D~ receptor  
m R N A  (fig. 1). While m R N A  levels are not necessary 
reflections of protein levels, the qualitative differences 
observed between mutat ions are not likely due to a 
lack of receptor  transcription. The  m R N A  levels in 
lanes 6 and 7 are somewhat  lower compared  to the 
o ther  lanes of  the Northern  blot; however, these results 
are not consistently observed across experiments.  Simi- 
larly, co-transfection results with /3-gal that is mea- 
sured in eve~'  experiment  suggest that transfection 
efficiency was equivalent  across mutant  and wild type 
D e receptors  (data not shown). 
3.3. Aspartate (114) mutations 
Mutat ion of the negatively charged aspartate (114) 
residue in TM3 to e i ther  asparagine or  glycine pro- 
duced a dramatic loss of  binding affinity for both 
agonists and antagonists. Saturation studies with both 
[~H]raclopride (tab!e 2) and [3H]N-0437 (tz~ble 3) failed 
to demonstrate  a n j  consistent dopaminergic  receptor 
binding with aspanate  nmtations to ei ther asparagine 
or glycine, These effects have been replicated over  a 
series of studies and suggest that the negative charge of 
this aspartate is critical for D e receptor  binding. 
3.4. Serine 194 attd 197 mutations 
Individual mutation of serines 194 and 197 in TM5 
to alan±he produced asymmetrical effects on dopamine 
receptor  binding. Saturation studies with antagonist 
[3H]raclopride (tabie 2) and competi t ion studies with 
[3H]N-0437 (table 4) suggest that serine 197 may be 
differentially important for dopaminergic  binding. As 
can be seen from table 2, el imination of the potential 
hydrogen bonds with the serine 197 mutation produced 
a 4-fold reduction in [3H] ~aclopride binding affinity. 
In contrast,  similar mutations of serine 194 to alanine 
had no effect on raclol=ride affinity. 
Surprisingly, individual serine mutations in position 
194 and 197 had no effect on the binding affinity of 
agonist [3H]N-0437 as determined by saturations stud- 
its (table 3). Interestingly, however, competi t ion stud- 
ies using this ligand suggcst that this is not the case for 
other  dopaminergic agonists (table 4). While the loss of 
dopamincrgic  binding affinity varied with agonist, all 
TABt.E 4 
K, values (nM ± S.D.) of dopamine receptor agonMs competing with 
[ 3H]N-0437. 
Serlq4-Ab Scr197-Ala Wild type 
Apomorphine 5.01 _+ 1.48 89.0 ± 17.0 '~ 2.78± 0.43 
Br(mlocripline 1.6(t± 0.19 3.45 ± (I.6 " 1.82_+ (1,31 
Dopamine 488.0 ±134.0 1,270,0 ±270.0 ~' 152.0:5:36.t] 
LYt71555 114.0 ± 52.¢1 1.231k0 ±44(1.0" 217.0 ±14.0 
NPA 2.18± 0.57 39,6 ± 3.6" 0.82_+ 0.!0 
Two-way ANOVA indicated there were .-dgnificant differences for 
drug (F = 60.2, P < 0.00011. serinc mutatkm (F = 63.1, P < 0.0001) 
and drug',< mutation interaction (F = 19.6, P < 0.0001 ). The affinity 
for all agonists tested was significantly reduced with the serine 197 
mutation as compared to the wild type (" P < 0.05). The affinity of 
all the agonists tested was. not altered significantly with scrim." 194 
mutations as compared to the wild type. 
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TABLE 5 
K i values (nM :): S.D.) of dopamine receplor anlagonists competing 
with [~H]raclopride. 
Ser!S I-Ala Ser197-Ala Wild type 
( + )-Butaclamol 0.243 ± 11.0,')6 i}.265 ± 0.119 0.2301 ± 0.025 
Clozapinc 75.6 ±6.8 ~' 27.7 _+2.1 41.2 ±5.8 
Chlorpmmazine 0.798±0.143 ~' 0.227+0.040 '~ 0.472 _+_0.(t28 
Spiperone 0.079 ± 0.008 0.298 + O,(ll a {}.Or)6 ± 0.046 
Two-way ANOVA indicatgd there were significant differences for 
drug (F = 925.5, P < 0.(}It01), serine mutation (F = 101.9, P < 0.I)001 ) 
and drug x mutation interaction (F = 81.8, P . 0.0(R)I). :' Mutations 
that significantly differed from the wild type (P < 0.05). With the 
exception of (+}-hutaclamol. the affinity of the :~ther antag(;nisls 
tested was significantly different (P < {}.05) for the serinc 194 muta- 
lion as compared to serine 197. 
compounds tested showed a substantially greater loss 
of binding affinity with serine mutations in position 197 
as compared to 194 (table 4). Apomorphinc and NPA 
showed the largest effect with a 30-48-fo!d shift in K i 
with serine 197 mutations. Mutation of serine 194 
produced only modest 2- to 3-fold shifts in affinity to 
dopamine, apomorphinc and NPA that were not signif- 
icantly different from the wild type. In addition to both 
drug and mutant effects, statistical analysis further 
suggested a drug-mutation interaction, indicating t aat 
the serine 197 mutation may have produced an altered 
receptor binding profitc. The rank order of agonists 
tested in competition with [3H]N-0437 varies wD.'n 
comparing the D 2 wild type and the scrine 197 muta- 
tion. 
The importance of scrincs 194 and 197 for antago- 
nist binding is less clear. Competition studies (table 5) 
with a number of antagonists suggest that scrinc 197 
may not be important for most antagonists tested, as 
the affinity for (+)-butaclamol, clozapine and chlor- 
promazine is not reduced by this mutation. However, 
as seen with [3H]raclopride, there was a 3-fold reduc- 
tion in affinity for spipcrone with a serine 197 muta- 
tion. Small differences in affinity (less than 2-fold) for 
clozapine and chlorpromazine were seen with the scr- 
ine 194 mutation; however, the significance of this 
slight shift is umclear. Again, two-way analysis of vari- 
ance demonstrated a drug-mutation interaction, sug- 
gesting that these serine mutations may alter the bind- 
ing profile and relative affinities of antagonists for the 
D 2 receptor. 
Dual mutations of serine 194 and 197 to alanine 
produced a nearly complete loss of specific [3H]N-0437 
binding (table 3). While dual serine 194 and 197 muta- 
tions also produced a somewhat greater loss in binding 
affinity for [3H]raclopride than mutations of serine 197 
alone, the effects were comparatively small and not 
statistically significant. 
3. 5..Methionble 116 and methionine 117 mutations 
Individual methionine mutations in positions 116 
and 117 to leucine and cysteinc, as well as dual muta- 
tions in these positions, failed to produce a change in 
the selectivity of the dopamine receptor. There was no 
enhanced adrenergic binding as measured by satura- 
tion studies with the adrenergic antagonist cyanopin- 
dolol or by competition sttMies with epinephrine and 
[3H]N-0437. No differences in [1251]CYP binding were 
observed between untransfected COS cells or COS 
cells transfected with the wild type D 2 or individual 
and dual methionine mutations (data not shown). Simi- 
larly, epinephrine did not display an enhanced affinity 
in displacing [3H]N-0437 binding in cells transfected 
with the methionine mutants compared to the wild 
type control. Met (116) and Met (117) mutations also 
failed to show any change in affinity to [3H]raclopride 
or [3H]N-0437 as compared to the wild type D:. 
4. Discussion 
Despite the structural similarities of the adrenocep- 
tors and dopamine receptors, these results suggest that 
there arc substantial differences in the way cate- 
cholamines interact with their respective binding pock- 
ets. The scrine mutations in position 194 and 197 failed 
to discriminate agonists from antagonists, as was the 
case for the/3e-adrenoceptor, and, as will be explained 
more fully below, dopamine likely binds in a different 
orientation in the D~ receptor pocket as compared to 
epinephrine and norepinephrine in the adrenoceptor 
pocket. Statistical analysis of the serine mutation bind- 
ing results demonstrates a drug-mutation interaction, 
suggesting that the binding profile or the rank order of 
agonists and antagonists may bc altered by these rnuta. 
tions, further emphasizing the importance of examining 
a wide series of compounds in evalu-~ti,~ th,, effects of 
receptor mutations. 
Whi!c clearly a concern, it is unlikely that the effects 
that have been observed with the aspartate, serine or 
methionine mutations are due to nonspecffic effects, 
such as the lack of receptor expression and variable 
transfection efficiency. Northern analysis indicates that 
all mutant receptor mRNAs were expressed and mea- 
surement of B-gal act~dty suggests ~hat efficiency of 
transfcction is an tmlikely factor in interpreting these 
results. While these controls do not guarantee that D 2 
mutant proteins were expressed correctly, the unal- 
tered affinities for N-0437 for the single serine and 
dual methionine mutations argue that the proteins 
formed by these mutant receptors are essentially intact. 
Similarly, mutants with dual seri.~e mutations which 
showed no binding with [3H]N-0437, exhibited substan- 
tial binding with [3H]raclopride. With regard to the 
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aspartate mutation, similar mutations in the /~2-r ;ccp- 
tor did not produce an aberrantly expressed protein 
(Strader et al., 1987b). 
Consistent with the D 2 receptor model proposed by 
Hibert et al. (1991), the results clearly demonstrate the 
importance of the negatively charged aspartate (114) 
for both dopaminergic agonist and antagonist binding. 
Elimination of the negative charge ~'~' mutating this 
critical amino acid to either asparagine or glycine 
markedly reduced the affinity of both agonists and 
antagonists to the D 2 receptor. As is the case for the 
adrenoceptor, the negative charge of Asp (114) of the 
D 2 receptor likely forms a salt bridge with the amino 
group of dopaminergic ligands, stabilizing the binding 
to the receptor. The aspartate residue (i14) in TM3 
serves as a possible anchoring point, then, to which all 
catecholamines likely bind. Aspartate 80 of the D 2 
receptor, on the other hand, is primarily important 
only for agonist binding and may be involved in induc- 
ing the conformation changes necessary for G-protein 
coupling (Neve et at., 1991). 
Unlike the /32-adrenoceptors in which both serines 
in TM5 are equally important for agonist binding, 
corresponding serines in the D 2 receptor (194 and 197) 
appear to be asymmetrically involved. Mutation of ser- 
ine 197 to alanine produced far greater decreases in 
agonist affinities compared to mutation of serine 194. 
Given that the amino group of dopamine is likely 
anchored at aspartate 114, the recta- and para-hydrox- 
y!s of the catechol moiety are free to form hydrogen 
bonds with either serine 194 or serine 197. Structure- 
activity studies, however, have demonstrated that the 
recta-hydroxyl group is of primary importance for 
dopaminergic activity, with the para-hydroxyl group 
having only an accessory func~i~a (Seeman, i~)81, ..'or 
review). The recta-hydroxyl D-nap of N-n-pro- 
pylnorapomolphinc, for cxan:pie, is sufficient for 
dopamine receptor binding and the addition of the 
para-hydroxyl group enhances binding affinity only 9 -  
10-fold The mutagenesis results pointing to the pri- 
mary. importance of serine i97 and these pharmacolog- 
ical data would suggest, then, that dopaminergic bind- 
ing is stabilized by hydrogen bonds formed between the 
meta-hydrox3'l group and serine 197, while the para-hy- 
droxyl group forms hydrogen bonds with serine 194. 
This orientation for dopamine in the D 2 receptor 
pocket differs markedly from norepinephrine in the 
132-receptor, where the recta- and the para-hydroxyl 
groups form hydrogen bonds with serines 204 and 207, 
respectively (Strader et al., 1989a). It also appears to 
be different from the a2-receptor where the para-hy- 
droxyi group epinephrine is more important for [igand 
affinity compared to the recta-hydroxyl group (Wang et 
al., 1991). 
Also, unlike the adrenoceptors, mutations of serine 
194 and i97 of the D,  receptor did not produce 
selective changes in agonists. Serine 197 mu;ations 
produced a 4- to 5-fold decrease in affinity for raclo- 
pride and a 3-fold change in affinity for spiperone, two 
D~ antagonists. Examination of the structures of raclo- 
pride and sp!perc.ne and computer modeling of the D 2 
receptor (H.bert et al., !991; and this laboratory), 
suggest that unlike the other antagonists, both of these 
compounds could form hydrogen bonds with serine 197 
(fig. 2). I -  the case of rac!opride it is the carbonyl, 
while in spiperone it is the cyclic anaide proton that 
likely forms hydrogen bonds with serine 197. Mutation 
of serine 197 to alanine would eliminate these possible 
hydrogen bonds and reduce raclopride's and spiper- 
one's binding affinities. These suggestions are specula- 
tive, but tiaey provide a possible fi'amework for inter- 
preting the receptor binding results. Other antagonists, 
such as (+)-butaclamol, showed no effect with the 
serine mutations, while ctozapine and chlorpromazine 
did not show a reduced affinity by the serine 197 
mutation, but were slightly affected by serine 194 mu- 
tations. 
In general, agonist affinities were more greatly af- 
fected than antagonists by serine mutations 194 and 
197. This is clearly evident flora the dual serine muta- 
tions which resulted in a complete loss of agonist 
binding and only a 4-fold change in ractopride binding. 
Single serine 197 mutations similarly produced com- 
paratively large (30- to 56-fold) decreases in apomor- 
phine and NPA affinities. The oreeise loss of binding 
affinity with the serine 194 and 197 mutations is largely 
dependent on the agonis~ tested, suggesting that vari- 
ous dopaminergic drugs may bind in the pocket in 
subtly different ways. In the case of apomorphine and 
dopamine, for example, there are two hydroxyl groups 
in the meta and para positions, respectively, that can 
form hydrogen bonds with serine t94 and 197, while 
LY171555 has only one site capable of forming a 
hydrogen bond (fig. 2). If the quaternary nitrogen of 
LY171555 is aligned near the negative center of aspar- 
tare 114, then the only hydrogen within the ligand 
capable of forming a hydrogen bond would be nosi- 
tinned adjacent to serine 197. This observation, while 
speculative, is consistent with the binding results which 
demonstrate that a nmtation of serine 197 produces a 
5-6-fold decrease in LY171555 binding affinity, while a 
similar mutation of serine 194 produces no change in 
LY17t555 affinity. 
Of the agonists tested, N-0437 is particularly inter- 
esting as single serine 194 or 197 mutations produced 
no cffcci, on its binding affinity, while dua! serine 
mutations produced a complete lo~.s of specific binding. 
Structurally, N-0437 is a very flexible compound whose 
phenol group may be capable of free rotation (fig. 2) 
and interacting with, and being stabilized by either 
serine 194 or 197. It is only with dual serine mutations 
that the binding of N-0437 is affected. It will be inter- 
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esting in future studies to examine whether receptors 
with single serine 194 or 197 mutations will be able to 
couple to G-proteios and whether N-0437 can induce 
an inhibition of cAMP. 
Neither individual nor dual methionine mutations 
designed to more closely approximate ~he /3z-adreno- 
ceptor produced a change in dopamine receptor selec- 
tivity. Direct binding studies with [125I]CYP failed to 
demonstrate a change in binding affinity or capacity 
with each of the methionine mutants tested. Similarly, 
competition studies suggested that epinephrine's affin- 
ity was not enhanced by methioni~e mutations in posi- 
tions 116 and 117. Perhaps single or dual amino acid 
mutations are not sufficient to altea receptor selectivity 
and domain swapping of longer amino acid stretches 
are necessary. For example, the transfer of TM7 of the 
a,2-receptor was necessa~ to confer ~2 binding charac- 
teristics to the /3:-receptor (Kobi!ka et a l ,  1988). Simi- 
larly here, larger domain switching 0etween the 
adrenoceptors and dopamine receptors in the form of 
chimeras may be necessary to alter the selectivity of 
the dopamine receptor. 
In summary., while aspartate (1 t4) is absolutely criti- 
cal for binding, the role of the two serines (194 and 
197) in TM5 appears to differ as a function of the 
nature of the ligand. The serine mutations 194 and 197, 
while producing more dramatic effects on agonists, did 
not result in a sharp distinction between agonists and 
antagonists as has been the case for the adrenoceptors. 
Beyond the critical anchoring at aspartate 114 there 
may be multiple ways for a ligand to occupy the bind- 
ing pocket and trigger the cascade of events which 
either result in or block the activation of G-protein 
events. The differential effects observed could be ex- 
plained by different planar orientations or by more 
dramatic differences in the way that different ligands 
fit within the putative D 2 binding pocket, such that 
some ligands may be stabilized by interacting with 
residues other than the two serines in TM5. Alterna- 
tively, the differentia! sensitivity of agonists to the 
mutatigns ceuld be due to differences in flexibility or 
rigidity of the ligands, and the possibility that interac- 
tions with a single serine may be sufficient. Future 
studies aim to further define the binding pocket of the 
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Fig. 2. Selected agonist and antagonist .structut~.s as they may interac, in the D 2 receptor pocket. Sites of interaction with asparla;c ! 14 and 
serine 194 and 197 are based on binding results presented here and computer modeling of the D 2 receptor. 
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dopamine receptors and the residues involved in com- 
formationa!iy changing the receptor to induce changes 
in G-protein coupling and signal transduction, 
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